Filtered By:
Cancer: Squamous Cell Carcinoma
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 483 results found since Jan 2013.
Intratumoral Bacteria as Mediators of Cancer Immunotherapy Response
Cancer Res. 2023 Sep 15;83(18):2985-2986. doi: 10.1158/0008-5472.CAN-23-1857.ABSTRACTMultiple lines of evidence spanning from animal models to human clinical trials indicate that the microbiome influences cancer immunotherapy response. Whereas initial studies focused exclusively on the gastrointestinal (gut) microbiota-tumor axis, more recent studies have examined the possibility that bacteria located within tumor cells or within the tumor microenvironment mediate cancer treatment response. Strikingly, this phenomenon has been demonstrated in cancers that arise in anatomic locations that are traditionally thought to be dev...
Source: Cell Research - September 15, 2023 Category: Cytology Authors: Karen S Sfanos Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
The level of macrophage migration inhibitory factor is negatively correlated with the efficacy of PD-1 blockade immunotherapy combined with chemotherapy as a neoadjuvant therapy for esophageal squamous cell carcinoma
CONCLUSION: Baseline MIF levels were negatively correlated with neoadjuvant therapy efficacy. Thus, MIF may serve as a predictive biomarker for this therapy. The accuracy of the prediction could be improved if the serum concentration of MIF is measured again after the patient received several weeks of treatment.PMID:37678132 | DOI:10.1016/j.tranon.2023.101775
Source: Translational Oncology - September 7, 2023 Category: Cancer & Oncology Authors: Liangliang Wu Yiming Gao Shengzhi Xie Wan Ye Yasushi Uemura Rong Zhang Yanju Yu Jinfeng Li Man Chen Qiyan Wu Pengfei Cui Hongyu Liu Shuai Mu Yilan Li Lingxiong Wang Chunxi Liu Jiahui Li Lijun Zhang Shunchang Jiao Guoqing Zhang Tianyi Liu Source Type: research
Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma
Oral Oncol. 2023 Sep 2;146:106562. doi: 10.1016/j.oraloncology.2023.106562. Online ahead of print.ABSTRACTHead and neck squamous cell carcinomas (HNSCC) are associated with significant treatment-related morbidity and poor disease-free and disease-specific survival, especially in the recurrent and metastatic (R/M HNSCC) setting. Inhibition of the programmed death-1/ligand-1 (PD-1/PD-L1) immune checkpoint is accepted as a first-line treatment strategy for R/M HNSCC and has expanded into the neoadjuvant, definitive, and adjuvant settings. To understand cellular signals modulating the PD-L1 in HNSCC, we profiled a HNSCC cell-l...
Source: Ann Oncol - September 4, 2023 Category: Cancer & Oncology Authors: Jacqueline E Mann Joshua D Smith Aditi Kulkarni Susan K Foltin Erin B Scheftz Isabel R Murray Elizabeth Gensterblum-Miller Collin V Brummel Apurva Bhangale Rebecca C Hoesli J Chad Brenner Source Type: research
Effect of neoadjuvant therapy on serum transforming growth factor- β, squamous cell carcinoma associated antigen, and prognosis in patients with locally advanced esophageal cancer
Cell Mol Biol (Noisy-le-grand). 2023 May 31;69(5):112-118. doi: 10.14715/cmb/2023.69.5.18.ABSTRACTIt was to explore the effect of neoadjuvant therapy (NAT) on serum-related indicators and prognosis of patients with locally advanced esophageal cancer (EC). 400 EC patients were grouped as controls (295 cases, radical EC resection alone) and research group (105 cases, NAT plus radical EC resection). The levels of serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), programmed death-1 (PD-1), PD-2, transforming growth factor-β1 (TGF-β1), and squamous ...
Source: Mol Biol Cell - August 12, 2023 Category: Molecular Biology Authors: Ruirui Zhang Wenze Tian Huanyu Zhao Zhengwei Zhang Jian Wu Su'an Sun Haiyan Liu Source Type: research
Correspondence Regarding "Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study"
JTO Clin Res Rep. 2023 Jul 5;4(8):100548. doi: 10.1016/j.jtocrr.2023.100548. eCollection 2023 Aug.NO ABSTRACTPMID:37554348 | PMC:PMC10405297 | DOI:10.1016/j.jtocrr.2023.100548
Source: Clinical Genitourinary Cancer - August 9, 2023 Category: Cancer & Oncology Authors: Kazuki Takada Shinkichi Takamori Source Type: research
